Optimal management of atypical hemolytic uremic disease: challenges and solutions

References

• George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371:654–666. doi:10.1056/NEJMoa141049025119611
   PubMed Web of Science ®Google Scholar
• Amorosi E, Ultmann J. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine. 1966;45:139–159. doi:10.1097/00005792-196603000-00003
   Web of Science ®Google Scholar
• Noris M, Remuzzi G. Atypical hemolytic–uremic syndrome. N Engl J Med. 2009;361:1676–1687. doi:10.1056/NEJMra090281419846853
   PubMed Web of Science ®Google Scholar
• Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108:1267–1279. doi:10.1182/blood-2006-03-01333416621965
   PubMed Web of Science ®Google Scholar
• Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007;18(8):2392–2400. Epub 2007 June 28. doi:10.1681/ASN.200608081117599974
   PubMed Web of Science ®Google Scholar
• Laurence J. Atypical hemolytic uremic syndrome (aHUS): making the diagnosis. Clin Adv Hematol Oncol. 2012;10(10 S17):1–12.
   Google Scholar
• Noris M, Bucchioni S, Galbusera M, et al. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J Am Soc Nephrol. 2005;16(5):1177–1183. doi:10.1681/ASN.200501008615800115
   PubMed Web of Science ®Google Scholar
• Ohanian M, Cable C, Halka K. Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome. Clin Pharmacol. 2011;3:5–12. Epub 2011 May 24. doi:10.2147/CPAA.S1790422287852
   PubMedGoogle Scholar
• Dragon-Durey MA, Sethi SK, Bagga A. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol. 2010;21(12):2180–2187. Epub 2010 Nov 4. doi:10.1681/ASN.201003031521051740
   PubMed Web of Science ®Google Scholar
• Al-Akash SI, Almond PS, Savell VH Jr, Gharaybeh SI, Hogue C. Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol. 2011;26(4):613–619. Epub 2010 Dec 2. doi:10.1007/s00467-010-1708-621125405
   PubMed Web of Science ®Google Scholar
• Sallée M, Daniel L, Piercecchi MD, et al. Myocardial infarction is a complication of factor H-associated atypical HUS. Nephrol Dial Transplant. 2010;25(6):2028–2032. Epub 2010 Mar 19. doi:10.1093/ndt/gfq16020305136
   PubMed Web of Science ®Google Scholar
• Noris M, Remuzzi G. Cardiovascular complications in atypical hemolytic uremic syndrome. Nat Rev Nephrol. 2014;10:174. doi:10.1038/nrneph.2013.28024419569
   PubMed Web of Science ®Google Scholar
• Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2008;23(11):1957–1972. Epub 2008 Jul 2. doi:10.1007/s00467-008-0872-418594873
   PubMed Web of Science ®Google Scholar
• Larakeb A1, Leroy S, Frémeaux-Bacchi V, et al. Ocular involvement in hemolytic uremic syndrome due to factor H deficiency--are there therapeutic consequences? Pediatr Nephrol. 2007;22(11):1967–1970. Epub 2007 Jul 10. doi:10.1007/s00467-007-0540-017619907
   PubMed Web of Science ®Google Scholar
• Zheng X, Gorovoy IR, Mao J, Jin J, Chen X, Cui QN. Recurrent ocular involvement in pediatric atypical hemolytic uremic syndrome. J Pediatr Ophthalmol Strabismus. 2014;51:e62–5. doi:10.3928/01913913-20140923-03
   Web of Science ®Google Scholar
• Raina R, Krishnappa V, Blaha T, et al. Atypical hemolytic uremic syndrome: an update on pathophysiology, diagnosis, and treatment. Ther Apher Dial. 2019;23(1):4–21. doi:10.1111/1744-9987.1276330294946
   PubMed Web of Science ®Google Scholar
• Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;38:817–824.
   Google Scholar
• Moskovich O, Fishelson Z. Live cell imaging of outward and inward vesiculation induced by the complement C5b‐9 complex. J Biol Chem. 2007;282(41):29977–29986. doi:10.1074/jbc.M70374220017644516
   PubMed Web of Science ®Google Scholar
• Walport MJ. Complement. First of Two Parts. N Engl J Med. 2001;344(14):1058–1066. doi:10.1056/NEJM20010405344140611287977
   PubMed Web of Science ®Google Scholar
• Noris M, Remuzzi G. Overview of complement activation and regulation. Semin Nephrol. 2013;33(6):479–492. doi:10.1016/j.semnephrol.2013.08.00124161035
   PubMed Web of Science ®Google Scholar
• Licht C, Kirsch M. The role of complement in disease In: Geary D, Schaefer F, editors. Pediatric Kidney Disease. Berlin (Heidelberg): Springer; 2016:583–596.
   Google Scholar
• Vaisbich MH. Hemolytic-uremic syndrome in childhood. J Bras Nefrol. 2014;36(2):208–220.25055362
   PubMedGoogle Scholar
• Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844–1859. doi:10.2215/CJN.0221031020595690
   PubMed Web of Science ®Google Scholar
• Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169–2181. doi:10.1056/NEJMoa120898123738544
   PubMed Web of Science ®Google Scholar
• Krisinger MJ, Goebeler V, Lu Z. Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood. 2012;120(8):1717–1725. Epub 2012 July 16. doi:10.1182/blood-2012-02-41208022802338
   PubMed Web of Science ®Google Scholar
• Stuhlinger W, Kourilsky O, Kanfer A, Sraer JD. Letter: haemolytic-uraemic syndrome: evidence for intravascular C3 activation. Lancet. 1974;2:788–789. doi:10.1016/S0140-6736(74)90991-X
   PubMed Web of Science ®Google Scholar
• Lemaire M, Frémeaux-Bacchi V, Schaefer F, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet. 2013;45(5):531–536. Epub 2013 Mar 31. doi:10.1038/ng.259023542698
   PubMed Web of Science ®Google Scholar
• Michon B, Moghrabi A, Winikoff R, et al. Complications of apheresis in children. Transfusion. 2007;47(10):1837–1842. doi:10.1111/j.1537-2995.2007.01405.x17880609
   PubMed Web of Science ®Google Scholar
• Palma LM, Langman CB. Critical appraisal of Eculizumab for atypical hemolytic uremic syndrome. J Blood Med. 2016;7:39–72. doi:10.2147/JBM.S3624927110144
   PubMed Web of Science ®Google Scholar
• Cao M, Leite BN, Ferreiro T, et al. Eculizumab modifies outcomes in adults with atypical hemolytic uremic syndrome with acute kidney injury. Am J Nephrol. 2018;48(3):225–233. Epub 2018 Sep 11. doi:10.1159/00049286530205388
   PubMed Web of Science ®Google Scholar
• Kato H, Miyakawa Y, Hidaka Y, et al. Safety and effectiveness of Eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clin Exp Nephrol. 2018;23(1):65–75. doi:10.1007/s10157-018-1609-829959568
   PubMed Web of Science ®Google Scholar
• Greenbaum L, Legendre CM, Babu S, et al. Eculizumab (ECU) in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Progressing Thrombotic Microangiopathy (TMA): 2-year data. Blood. 2012;120(21):2084.
   Web of Science ®Google Scholar
• Wijnsma KL, Duineveld C, Wetzels JFM, et al. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatr Nephrol. 2018. doi:10.1007/s00467-018-4091-3
   Web of Science ®Google Scholar
• Schmidtko J, Peine S, El-Housseini Y, Pascual M, Meier P. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on Eculizumab. Am J Kidney Dis. 2013;61(2):289–299. Epub 2012 Nov 7. doi:10.1053/j.ajkd.2012.07.02823141475
   PubMed Web of Science ®Google Scholar
• Harder MJ, Kuhn N, Schrezenmeier H, et al. Incomplete inhibition by Eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. Blood. 2017;129(8):970–980. doi:10.1182/blood-2016-08-73280028028023
   PubMed Web of Science ®Google Scholar
• Soliris (Eculizumab) highlights of prescribing information.US Food and Drug Administration. 2007 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125166s172lbl.pdf Accessed 228, 2019.
   Google Scholar
• Wijnsma KL, Ter Heine R, Moes DJAR, et al. Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab. Clin Pharmacokinet. 2019;58(7):859–874. doi:10.1007/s40262-019-00742-8
   Web of Science ®Google Scholar
• Krishnappa V, Gupta M, Shah H, et al. Atypical hemolytic uremic syndrome: a meta-analysis of case reports confirms the prevalence of genetic mutations and the shift of treatment regimens. Ther Apher Dial. 2018;22:178–188. doi:10.1111/1744-9987.1264129250893
   PubMed Web of Science ®Google Scholar
• Rathbone J, Kaltenthaler E, Richards A, Tappenden P, Bessey A, Cantrell A. A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open. 2013;3:e003573. doi:10.1136/bmjopen-2013-003573
   PubMed Web of Science ®Google Scholar
• Licht C, Greenbaum LA, Muus P, et al. Efficacy and safety of Eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015;87:1061–1073. doi:10.1038/ki.2014.42325651368
   PubMed Web of Science ®Google Scholar
• Cofiell R, Kukreja A, Bedard K, et al. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood. 2015;125:3253–3262. doi:10.1182/blood-2014-09-60041125833956
   PubMed Web of Science ®Google Scholar
• Cavero T, Rabasco C, Lopez A, et al. Eculizumab in secondary atypical hemolytic uraemic syndrome. Nephrol Dial Transplant. 2017;32:466–474. doi:10.1093/ndt/gfw45328339660
   PubMed Web of Science ®Google Scholar
• Walle JV, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of Eculizumab treatment. J Nephrol. 2017;30:127–134. doi:10.1007/s40620-016-0288-326995002
   PubMed Web of Science ®Google Scholar
• Greenbaum LA, Fila M, Ardissino G, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016;89:701–711. doi:10.1016/j.kint.2015.11.02626880462
   PubMed Web of Science ®Google Scholar
• Kumar G, Al-Masri O, Alismaili Z, et al. Eculizumab in pediatric atypical hemolytic uremic syndrome: lessons learned from a single center experience in the United Arab Emirates. J Paediatr Child Health. 2019. doi:10.1111/jpc.14390
   Web of Science ®Google Scholar
• Fakhouri F, Hourmant M, Campistol JM, et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis. 2016;68(1):84–93. doi:10.1053/j.ajkd.2015.12.03427012908
   PubMed Web of Science ®Google Scholar
• Merrill SA, Brittingham ZD, Yuan X, Moliterno AR, Sperati CJ, Brodsky RA. Eculizumab cessation in atypical hemolytic uremic syndrome. Blood. 2017;130:368–372. doi:10.1182/blood-2017-02-77021428461395
   PubMed Web of Science ®Google Scholar
• Huerta A, Arjona E, Portoles J, et al. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney Int. 2018;93:450–459. doi:10.1016/j.kint.2017.06.02228911789
   PubMed Web of Science ®Google Scholar
• aHUS Global Patients’ Research Agenda. aHUS Alliance, consensus document released. 2 28, 2019 Available from: https://bit.ly/2UH5nZc. Accessed 723, 2019.
   Google Scholar
• Burke L, Woodward L, Shah KD. Graphs & Insights - Results from the 2016 aHUS Global Poll. aHUS Alliance. 7 2016 Article Available from: https://bit.ly/2FXtFpW. Accessed 723, 2019.
   Google Scholar
• Access to aHUS Treatment: 2016 aHUS Global Poll White Paper. Orphan drug access – are rare disease treatments like eculizumab equally available worldwide? Available from: https://bit.ly/2VtqgnZ. Accessed 723, 2019.
   Google Scholar
• Karpman D, Höglund P. Orphan drug policies and use in pediatric nephrology. Pediatr Nephrol. 2017;32:1–6. doi:10.1007/s00467-016-3520-427738765
   PubMed Web of Science ®Google Scholar
• Gottlich E, McCulloch M South African paediatric nephrology perspective on eculizumab therapy for atypical HUS: a global review panel model for aHUS drug access. aHUS Alliance article. Available from: https://bit.ly/2Vw58h6. Accessed 723, 2019.
   Google Scholar
• Woodward L, Johnson S, Walle JV, et al. An innovative and collaborative partnership between patients with rare disease and industry-supported registries: the Global aHUS Registry. Orphanet J Rare Dis. 2016;11:154. doi:10.1186/s13023-016-0537-527871301
   PubMed Web of Science ®Google Scholar
• Goodship TH, Cook HT, Fakhouri F, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: improving Global Outcomes” (KDIGO) controversies conference. Kidney Int. 2017;91(3):539–551. Epub 2016 Dec 16. doi:10.1016/j.kint.2016.10.00527989322
   PubMed Web of Science ®Google Scholar
• Harris DCH, Davies SJ, Finkelstein FO, et al. Increasing access to integrated ESKD care as part of universal health coverage. Kidney Int. 2019;95(4S):S1–S33. doi:10.1016/j.kint.2018.12.00530904051
   PubMed Web of Science ®Google Scholar
• TMA Boston, link to article w. agenda Available from: https://bit.ly/2uPBo2G. Accessed 723, 2019.
   Google Scholar
• Gordon CE, Chitalia VC, Sloan JM, et al. Thrombotic microangiopathy: a multidisciplinary team approach. Am J Kidney Dis. 2017;70(5):715–721. doi:10.1053/j.ajkd.2017.05.01728720207
   PubMed Web of Science ®Google Scholar
• Ariceta G. Optimal duration of treatment with Eculizumab in atypical hemolytic uremic syndrome (aHUS)—a question to be addressed in a scientific way. Pediatr Nephrol. 2019;34(5):943–949.30693384
   PubMed Web of Science ®Google Scholar
• Burke L Atypical HUS therapeutic drug pipeline in 2018: drug discovery and market factors within the aHUS Arena. aHUS Alliance article. 5 2018 Available from: https://bit.ly/2OSHQ2h. Accessed 723, 2019.
   Google Scholar
• The rising cost of orphan drugs. Lancet Haematol. 2015;2(11):e456. doi:10.1016/S2352-3026(15)00229-X26686251
   PubMed Web of Science ®Google Scholar
• Sethi SK, Rohatgi S, Dragon-Durey MA, et al. Eculizumab for atypical hemolytic-uremic syndrome in India: first report from India and the challenges faced. Indian J Nephrol. 2017;27(1):58–61. doi:10.4103/0971-4065.17936928182046
   PubMedGoogle Scholar
• NICE (National Institute for Health and Care Excellence). Eculizumab for treating atypical haemolytic uraemic syndrome. Available from: https://www.nice.org.uk/guidance/hst1/resources/Eculizumab-fortreating-atypical-haemolytic-uraemic-syndrome-pdf. Published 1 2015 Accessed 228, 2019.
   Google Scholar
• Rodriguez-Monguio R, Spargo T, Seoane-Vazquez E. Ethical imperatives of timely access to orphan drugs: ispossible to reconcile economic incentives and patients’ health needs? Orphanet J Rare Dis. 2017;12(1):1. doi:10.1186/s13023-016-0551-728057032
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Alexion briefing information for the November 18, 2014, meeting of the Drug Safety and Risk Management Advisory Committee. Available from: https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/ucm423029.htm. Accessed 723, 2019.
   Google Scholar
• Managing the risk of meningococcal disease among patients who receive eculizumab therapy. Available from: https://www.cdc.gov/meningococcal/clinical/eculizumab.html Accessed 33, 2019.
   Google Scholar
• Cullinan N, Gorman KM, Riordan M, Waldron M, Goodship TH, Awan A. Case report: benefits and challenges of long-term Eculizumab in atypical hemolytic uremic syndrome. Pediatrics. 2015;135:e1506–e1509. doi:10.1542/peds.2014-350325941307
   PubMed Web of Science ®Google Scholar
• Struijk GH, Bouts AH, Rijkers GT, Kuin EA, Ten Berge IJ, Bemelman FJ. Meningococcal sepsis complicating Eculizumab treatment despite prior vaccination. Am J Transplant. 2013;13:819–820. doi:10.1111/ajt.1203223289494
   PubMed Web of Science ®Google Scholar
• Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31:15–39. doi:10.1007/s00467-015-3076-825859752
   PubMed Web of Science ®Google Scholar
• Loirat C, Fremeaux-Bacchi V. Anti-factor H autoantibody- associated hemolytic uremic syndrome: the earlier diagnosed and treated, the better. Kidney Int. 2014;85:1019–1022. doi:10.1038/ki.2013.44724786877
   PubMed Web of Science ®Google Scholar
• Schaefer F, Ardissino G, Ariceta G. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int. 2018;94(2):408–418. Epub 2018 Jun 19. doi:10.1016/j.kint.2018.02.02929907460
   PubMed Web of Science ®Google Scholar
• Bagga A, Khandelwal P, Mishra K, et al. Hemolytic uremic syndrome in a developing country: consensus guidelines. Pediatr Nephrol. 2019;34:1465–1482. Epub ahead of print. doi:10.1007/s00467-019-04233-730989342
   PubMed Web of Science ®Google Scholar
• Fakhouri F, Loirat C. Anticomplement treatment in atypical and typical hemolytic uremic syndrome. Semin Hematol. 2018;55:150–158. doi:10.1053/j.seminhematol.2018.04.00930032752
   PubMed Web of Science ®Google Scholar
• Volokhina E, Wijnsma K, van der Molen R, et al. Eculizumab dosing regimen in atypical HUS: possibilities for individualized treatment. Clin Pharmacol Ther. 2017;102:671–678. doi:10.1002/cpt.68628295239
   PubMed Web of Science ®Google Scholar
• Gatault P, Brachet G, Ternant D, et al. Therapeutic drug monitoring of Eculizumab: rationale for an individualized dosing schedule. mAbs. 2015;7(6):1205–1211. doi:10.1080/19420862.2015.108604926337866
   PubMed Web of Science ®Google Scholar
• Ardissino G, Tel F, Sgarbanti M, et al. Complement functional tests for monitoring Eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update. Pediatr Nephrol. 2018;33(3):457–461. Epub 2017 Oct 18. doi:10.1007/s00467-017-3813-229046944
   PubMed Web of Science ®Google Scholar
• Cugno M, Gaultierotti R, Possenti I, et al. Complement functional tests for monitoring Eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost. 2014;12(9):1440–1448. Epub 2014 Jul 16. doi:10.1111/jth.1261524853860
   PubMed Web of Science ®Google Scholar
• Ricklin D, Barratt-Due A, Mollnes TE. Complement in clinical medicine: clinical trials, case reports and therapy monitoring. Mol Immunol. 2017;89:10–21. doi:10.1016/j.molimm28576323
   PubMed Web of Science ®Google Scholar
• Noris M, Galbusera M, Gastoldi S, et al. Dynamics of complement activation in aHUS and how to monitor Eculizumab therapy. Blood. 2014;124(11):1715–1726. Epub 2014 Jul 18. doi:10.1182/blood-2014-02-55829625037630
   PubMed Web of Science ®Google Scholar
• Wehling C, Amon O, Bommer M, et al. Monitoring of complement activation biomarkers and Eculizumab in complement mediated renal disorders. ClinExp Immunol. 2017;187:304–315. doi:10.1111/cei.12890
   Web of Science ®Google Scholar
• Puissant-Lubrano B, Puissochet S, Congy-Jolivet N, et al. Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with Eculizumab. Clin Immunol. 2017;183:1–7. doi:10.1016/j.clim.2017.06.00728647502
   PubMed Web of Science ®Google Scholar
• Macia M, de Alvaro Moreno F, Dutt T, et al. Current evidence on the discontinuation of Eculizumab in patients with atypical haemolytic uraemic syndrome. Clin Kidney J. 2017;10:310–319. doi:10.1093/ckj/sfw11528621343
   PubMed Web of Science ®Google Scholar
• Fakhouri F, Fila M, Provôt F, et al. Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after Eculizumab discontinuation. Clin J Am Soc Nephrol. 2017;12:50–59. doi:10.2215/cjn.0644061627799617
   PubMed Web of Science ®Google Scholar
• Ardissino G, Possenti I, Tel F, Testa S, Salardi S, Ladisa V. Discontinuation of Eculizumab treatment in atypical hemolytic uremic syndrome: an update. Am J Kidney Dis. 2015;66:172–173. doi:10.1053/j.ajkd.2015.04.010
   PubMed Web of Science ®Google Scholar
• Wijnsma KL, Duineveld C, Volokhina EB, van Den Heuvel LP, van de Kar N, Wetzels JFM. Safety and effectiveness of restrictive Eculizumab treatment in atypical haemolytic uremic syndrome. Nephrol Dial Transplant. 2018;33(4):635–645. doi:10.1093/ndt/gfx19629106598
   PubMed Web of Science ®Google Scholar
• Sheerin NS, Kavanagh D, Goodship TH, Johnson S. A national specialized service in England for atypical haemolytic uraemic syndrome-the first years’ experience. QJM. 2016;109:27–33. doi:10.1093/qjmed/hcv08225899302
   PubMed Web of Science ®Google Scholar
• Le Quintrec M, Zuber J, Moulin B, et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant. 2013;13:663–675. doi:10.1111/ajt.1207723356914
   PubMed Web of Science ®Google Scholar
• Legendre CM, Campistol JM, Feldkamp T, et al. Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with Eculizumab: a pooled post hoc analysis. Transpl Int. 2017;30:1275–1283. doi:10.1111/tri.1302228801959
   PubMed Web of Science ®Google Scholar
• Siedlecki AM, Isbel N, Vande Walle J, et al. Eculizumab use for kidney transplantation in patients with a diagnosis of atypical hemolytic uremic syndrome. Kidney Int Rep. 2019;4(3):434–446. doi:10.1016/j.ekir.2018.11.01030899871
   PubMed Web of Science ®Google Scholar
• Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554–562. Epub 2013 Jan 10. doi:10.2215/CJN.0476051223307876
   PubMed Web of Science ®Google Scholar
• Noris M, Remuzzi G. Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. Curr Opin Nephrol Hypertens. 2013;22(6):704–712. doi:10.1097/MNH.0b013e328365b3fe24076560
   PubMed Web of Science ®Google Scholar
• Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011;6:60. doi:10.1186/1750-1172-6-6021902819
   PubMed Web of Science ®Google Scholar
• Pickering MC, de Jorge EG, Martinez-Barricarte R, et al. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med. 2007;204(6):1249–1256. Epub 2007 May 21. doi:10.1084/jem.2007030117517971
   PubMed Web of Science ®Google Scholar
• Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet. 2005;14(5):703–712. Epub 2005 Jan 20. doi:10.1093/hmg/ddi06615661753
   PubMed Web of Science ®Google Scholar
• Kavanagh D, Goodship TH, Richards A. Atypical haemolytic uraemic syndrome. Br Med Bull. 2006;77-78:5–22. Epub 2006 Sep 11. doi:10.1093/bmb/ldl00416968692
   PubMed Web of Science ®Google Scholar
• Kavanagh D, Goodship TH. Atypical hemolytic uremic syndrome, genetic basis, and clinical manifestations. Hematol Am Soc Hematol Educ Program. 2011;2011:15–20. doi:10.1182/asheducation-2011.1.15
   PubMed Web of Science ®Google Scholar
• Bresin E, Rurali E, Caprioli J, et al. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol. 2013;24(3):475–486. Epub 2013 Feb 21. doi:10.1681/ASN.201209088423431077
   PubMed Web of Science ®Google Scholar